Swiss pharma giant in Basel, shaping medicines and biotech strategy
Swiss voters have rejected the Swiss People’s Party initiative to cap the country’s population at 10 million by 2050, with roughly 55% voting against and 45% in favour. The measure would have forced stricter asylum and family-reunification rules once population hit 9.5 million and could have ended free movement with the EU if the 10 million limit were breached.
GSK has struck a multi-billion deal to acquire Nuvalent, adding three late-stage cancer drugs to its portfolio, including two lung-cancer therapies under FDA review. The acquisition aims to boost sales growth, expand the lung-cancer platform, and position GSK for a potential rise in annual revenue by 2031.